Related Experiment Video
Updated: Aug 19, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
Published on: October 22, 2014
Different effects of beta-1-adrenergic blocking agents with ISA or without ISA on peripheral blood flow
Insights
Celiprolol, a beta-blocker with ISA, did not affect peripheral blood flow in patients with or without peripheral arterial occlusive disease (PAOD). Metoprolol, without ISA, reduced blood flow and increased vascular resistance in these patients.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Medicine
Background:
- Beta-adrenergic blocking agents were historically contraindicated for peripheral arterial occlusive disease (PAOD).
- Recent studies suggest some beta-blockers may not negatively impact peripheral blood flow.
Purpose of the Study:
- To compare the effects of celiprolol (beta-1 blocker with ISA) and metoprolol (beta-1 blocker without ISA) on peripheral blood flow in patients with and without PAOD.
Main Methods:
- Acute trial: 24 patients (12 with PAOD, 12 without) received single doses of celiprolol or metoprolol in a double-blind crossover design.
- Long-term trial: Patients received daily doses of celiprolol or metoprolol for three weeks in a randomized double-blind design.
- Measurements included calf and skin blood flow at rest and during reactive hyperemia, basal vascular resistance (BVR), and minimal vascular resistance (MVR).
Main Results:
- Celiprolol did not significantly alter blood flow or vascular resistance in either group during acute or long-term treatment.
- Metoprolol significantly reduced muscle blood flow and increased BVR acutely in both groups.
- Long-term metoprolol treatment lowered calf blood flow at rest in PAOD patients and in non-PAOD patients, also increasing BVR in the latter.
Conclusions:
- Celiprolol appears safe for peripheral circulation in patients with and without PAOD.
- Metoprolol may negatively impact peripheral blood flow, particularly in patients with PAOD, warranting caution.
Abstract:
Until recently beta-adrenergic blocking agents were considered contraindicated in peripheral arterial occlusive disease (PAOD). However, in recent years several studies have failed to show negative effects on peripheral blood flow. It was the aim of this study to compare the effects of celiprolol, a beta-1-adrenergic blocking agent with intrinsic sympathomimetic activity (ISA), and of metoprolol, a beta-1-adrenergic blocking agent without ISA, on peripheral blood flow of patients with and without PAOD. In an acute trial 24 patients (group I: 12 patients with PAOD stage I and II; group II: 12 patients without PAOD received a single dose of 200 mg celiprolol or 200 mg metoprolol in a double-blind crossover design. Celiprolol induced no significant changes in calf and skin blood flow at rest or during reactive hyperemia. Basal vascular resistance (BVR) and minimal vascular resistance (MVR) were not affected. Metoprolol, however, significantly reduced muscle blood flow and increased BVR in both groups. Subsequently the patients were treated in a randomized double-blind design with a daily dose of 200 mg celiprolol or metoprolol for three weeks. In long-term treatment skin and muscle blood flow at rest and during reactive hyperemia, BVR, and MVR were not affected by celiprolol. Metoprolol significantly lowered calf blood flow at rest in patients with PAOD; other parameters remained unchanged. In patients without PAOD, metoprolol caused a significant decrease of calf blood flow at rest and an increase of BVR. Calf blood flow during reactive hyperemia, as well as skin blood flow at rest and during reactive hyperemia, showed no significant changes.(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
Related Concept Videos
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

